SAN

82.86

-0.3%↓

UCB

266

+3.18%↑

SHL.DE

36.34

+0.78%↑

ARGX

639

+3.23%↑

VIE

33.29

+0.79%↑

SAN

82.86

-0.3%↓

UCB

266

+3.18%↑

SHL.DE

36.34

+0.78%↑

ARGX

639

+3.23%↑

VIE

33.29

+0.79%↑

SAN

82.86

-0.3%↓

UCB

266

+3.18%↑

SHL.DE

36.34

+0.78%↑

ARGX

639

+3.23%↑

VIE

33.29

+0.79%↑

SAN

82.86

-0.3%↓

UCB

266

+3.18%↑

SHL.DE

36.34

+0.78%↑

ARGX

639

+3.23%↑

VIE

33.29

+0.79%↑

SAN

82.86

-0.3%↓

UCB

266

+3.18%↑

SHL.DE

36.34

+0.78%↑

ARGX

639

+3.23%↑

VIE

33.29

+0.79%↑

Strona główna・Stock List・ICADE.

ICADE.

Open

SectorHealthcare

19.78 2.38

Buy Sell

Overview

Share price change

24h

Current

Min

19.3

Max

19.88

Key metrics
By Trading Economics
Income	60M -31M
Sales	84M 707M
EPS	-0.41
Profit margin	-4.427
Employees	983
EBITDA	-152M -14M

Recommendations
By TipRanks
Recommendations	Strong Sell
12 Months Forecast	+3.99% upside

Market Stats
By TradingEconomics
Market Cap	-115M 1.5B
Previous open	17.4
Previous close	19.78

News Sentiment

By Acuity

50%

148 / 349 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

21.04 / 21.4 Support & Resistance

ICADE. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 mar 2026, 23:31 UTC

Hot Stocks

Stocks to Watch: Nike, RH, NCino

31 mar 2026, 22:35 UTC

Earnings

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 kwi 2026, 00:00 UTC

Acquisitions, Mergers, Takeovers

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mar 2026, 23:50 UTC

Acquisitions, Mergers, Takeovers

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mar 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mar 2026, 23:33 UTC

Market Talk

Major News Events

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mar 2026, 23:21 UTC

Earnings

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mar 2026, 23:14 UTC

Market Talk

Earnings

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mar 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Loss Widens >000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mar 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mar 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mar 2026, 21:35 UTC

Earnings

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Earnings

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Earnings

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mar 2026, 21:33 UTC

Acquisitions, Mergers, Takeovers

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mar 2026, 21:33 UTC

Earnings

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mar 2026, 21:32 UTC

Earnings

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mar 2026, 21:28 UTC

Earnings

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mar 2026, 21:26 UTC

Earnings

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mar 2026, 21:25 UTC

Earnings

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mar 2026, 21:24 UTC

Market Talk

Earnings

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mar 2026, 21:22 UTC

Earnings

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mar 2026, 21:22 UTC

Earnings

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mar 2026, 21:21 UTC

Earnings

Nike's Digital Channel Still Too Promotional, CFO Says

31 mar 2026, 21:20 UTC

Earnings

Nike CEO: Converse Remains Important to Portfolio

Peer Comparison

Price change

ICADE. Forecast

Price Target

By TipRanks

3.99% upside

12 Months Forecast

Average 19.82 EUR 3.99%

High 25 EUR

Low 17.1 EUR

Based on 5 Wall Street analysts offering 12 month price targets forICADE. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Sell

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to ICADE. - Dist in the past 3 months.

Technical Score

By Trading Central

21.04 / 21.4Support & Resistance

Recent bullish events outweigh bearish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

148 / 349 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ICADE.

Icade is a full-service real estate company with expertise in both commercial property investment (portfolio worth "6.8bn on a full consolidation basis as of 12/31/2023) and property development (2023 economic revenue of "1.3bn) that operates throughout France. Icade has forged longterm partnerships to respond to emerging trends in the industry. It has made climate issues and the preservation of biodiversity central to its business model to reinvent real estate and contribute to more sustainable cities. It is listed as a "SIIC" on Euronext Paris and its leading shareholder is the Caisse des Dépôts group.